We have a strong track record in process optimization and robust process development of peptide molecules. Our team is highly experienced in handling all forms of peptide synthesis viz. solid, solution, or hybrid phase peptides at our R&D centers in Hyderabad and Bangalore.
We have a dedicated peptide lab to support peptide synthesis, downstream purification, isolation and lyophilization.
As one of the leading CDMO, we have a state-of-the-art analytical laboratory for impurity characterization and profiling based on spectral methods.
We have one of the largest facilities to manufacture high-throughput synthesis of a wide variety of standard and complex peptides. We can manufacture various types of peptide classes with linear peptides up to 40 AA, conjugates of peptides such as small molecules, lipids, carbohydrates, and PEG. Cost effective LPPS approach for small peptides or linkers. We have expertise in process optimization and robust development for commercial manufacturing.
Our advanced technology with modern infrastructure enables us to produce up to 2 kg of linear and branched chain peptides. We provide peptide manufacturing services from our state-of- the-art manufacturing site in Vizag. The site is inspected by major regulatory bodies such as the US FDA, MHRA, and PMDA.
Class of peptides we handle
We can handle a wide range of peptides classes such as:
- Linear and branched chain peptides up to 40-mer AA (Natural and unnatural).
- Derivatives of peptides viz., small molecules/ carbohydrate/ PEG
- Peptides with multiple disulfide bridges, head-to-tail cyclization, and side-to-side cyclization
- Stappled, fluorescent and dyes.
- Cysteine rich peptides, lactam bridged peptides.
- Expertise in LPPS, SPPS and hybrid approaches
Lab infrastructure to support peptide development
Synthesizers
- Cost-effective LPPS approach for small peptides/linkers
- Manual reactors ranging from 100 mL to 10 L capacity (SPPS)
- CS Bio 936S: Automated peptide synthesizer fits for feasibility, optimization studies, pilot studies, and scale-up activities (1 to 5 L).
- CEM Automated Microwave Peptide Synthesizer-2 nos.
Lab -scale purification
- 3 preparative reverse phase HPLCs
- 1 MPLC flash system 250 mL/min pump capacity
- 1 Akta explorer ion exchange chromatography
- 1 Aktaprime plus ion exchange chromatography
- Gel permeation chromatography columns
Isolation techniques
- Crystallization
- Precipitation
- Lyophilization
- Virtis programmable tray of 3 L capacity
- Virtis benchtop of 1.5 L capacity
- Membrane filtration technology
- Tangential Flow Filtration (TFF) 1 kDa, 10kDa, and above
Analytical equipment to support peptide development
- LCMS, GC-MS, LC-Tof, LC Orbitrap, MALDI Tof instruments for characterization
- Multi-angle Light Scattering Detector (MALS)
- Circular Dichroism (CD) analysis for peptides
- 600 MHz nuclear magnetic resonance spectrometry
- Charged Aerosol Detector (CAD) for HPLC
- Amino acid analyzer with post-column derivatization
Clinical supply manufacturing
For your clinical supplies and commercial manufacturing needs, we provide peptide manufacturing services from our state-of-the-art manufacturing sites in Visakhapatnam. Both these sites are inspected by major regulatory bodies such as USFDA, MHRA, PMDA etc. Our facilities are equipped with microwave assist technology, liberty pro automatic synthesizers, and fully automated ion exchange purification systems.
Equipments for peptide synthesis
- Automated peptide synthesizer (80-160 L)
- Liberty pro peptide synthesizer (25 L)
- Microwave assisted peptide synthesizer
- Hastealloy ANFDs of 1m2 capacity for closed loop filtration operations
- Tangential flow filtration
- Separate peptide block (PB – 16) dedicated to peptides & polymers
Peptide purification and isolation
- Preparative RP-HPLC (150 to 600 mm diameter column, flow rate ranging from 3.3 to 20 LPH) with PAT blending technology.
- Fully automated ion exchange resin systems
- Freeze dryer – 100 L capacity (tray)
- Class 100K clean room area with Lyophilizers
Impurity profiling and characterization
- LCMS, GC-MS, LC-Tof, LC Orbitrap, MALDI Tof instruments for characterization
- Multi-angle Light Scattering (MALS) detector
- Circular Dichroism (CD) analysis for peptides
- 600 MHz nuclear magnetic resonance spectrometry
- Charged Aerosol Detector (CAD) for HPLC
- Amino acid analyzer with post-column derivatization
Why Aurigene Peptide Development and Manufacturing services?
Extensive knowledge in developing & manufacturing hundreds of complex pharmaceutical products
Seamless integration from discovery to manufacturing
Capabilities across a wide range of peptide molecules
Large manufacturing capacities with automatic synthesizers
Rethink processes to ensure better quality in shorter timelines
Apply new science and technologies, to reduce costs or risk and add innovation
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market